

<b>Customer Name</b>	Novaerus (Ireland) Ltd.
<b>Customer Address</b>	DCU Alpha, Old Finglas Road, Glasnevin, Dublin 11
<b>Contact</b>	Felipe Soberon
<b>Customer PO number</b>	n/a
<b>Test Requested</b>	To assess the impact of Air cleaner on Clostridium difficile spores
<b>Sample Description</b>	Novaerus air cleaner device (NV1050), 3 replacement filters (Ozone filter, Kompakfilter & Megalam panel filter)
<b>Number of Samples</b>	1 NV1050 and 3 x filters
<b>Date of Receipt</b>	06/04/2018
<b>ASC Code</b>	ASC003569, ASC003648, ASC003649
<b>Report Number</b>	ASCR092328
<b>Report Date</b>	08/02/2019

## Contents

1. Purpose .....	3
2. Test Item Description .....	3
3. Protocol .....	3
4. Results and Discussion:.....	5
4 Conclusion .....	6

## 1. Purpose


---

The purpose of the testing is to assess the performance of the Novaerus (NV1050) air purifier in removing aerosolised *Clostridium difficile* spores.

## 2. Test Item Description

---

The Novaerus (NV1050) air purifier was received by **airmid healthgroup** on 06/04/2018 (Figure 2.1).



## 3. Protocol

---

### 3.1. Test conditions:

- 3.1.1. The impact of Novaerus (NV1050) air purifier on aerosolised *C. difficile* spores (ATCC 43593) was conducted in the 28.5m<sup>3</sup> environmental test chamber.
- 3.1.2. The test chamber was pre-conditioned to 20 ± 3 °C and 55 ± 5% relative humidity. During testing, the air handling unit was shut down, which reduces the number of air changes to as close to zero as possible.

### 3.2. Test Procedure & Analysis:

- 3.2.1. A total of 6 runs were performed to test the impact of the The Novaerus (NV1050) air purifier on aerosolised *C. difficile* spores. (3 Test and 3 Control runs).
- 3.2.2. During the test runs the air purifier was placed in the centre of the test chamber and operated at full speed mode. During the control runs the air purifier was switched off.
- 3.2.3. The spores of the test organism were prepared under anaerobic conditions using an optimised in-house procedure. A detection kit was used to confirm that the spores were *Clostridium difficile*. They were diluted to a pre-determined concentration of  $10^5$  colony forming units (CFU) prior to nebulisation.
- 3.2.4. The *C. difficile* spores were nebulised into the chamber for a fixed time and mixed with a ceiling fan.
- 3.2.5. Biostage impactors were used to sample the air. The sampling points for both test and control runs were as follows:

Air sampling time-points			
Test Stage	Air Sampling Details	Time-point (t)	Sample Duration (min)
I	Immediately after nebulisation	-3 - 0	3
Air Purifier On (Test Runs)			
II	during run	15 - 20	5
III	during run	35 - 40	5

- 3.2.6. At each sampling point, triplicate air samples were collected.
- 3.2.7. For the test runs, the air purifier was turned on remotely at t=0 min and operated throughout the test period.
- 3.2.8. At the end of the test, the test chamber was set to full air dump. The agar plates were removed from the biostage impactors and brought to the laboratory.
- 3.2.9. After each run, the test chamber was decontaminated by exposing the walls and floor to 5% Bleach and rinsing with water. The chamber surfaces were then exposed to UV lamps for at least 120 mins with full air dump.
- 3.2.10. The agar plates were incubated at 37 °C for 24 hrs under anaerobic conditions.
- 3.2.11. After 24 hrs, the number CFU's on the plates were counted, corrected for positive hole correlation and converted to CFU per cubic meter of air sampled ( $CFU/m^3$ ).  $CFU/m^3$  results were then converted to  $Log_{10}$  values for the graph.



3.2.12. The % Reduction was calculated from the following formula:

$$\begin{aligned} & \text{\% Reduction at } t = x: \\ & = 100 - \left( \frac{\text{Bacteria spore CFU/m}^3 \text{ with A/C on at } t = x}{\text{Bacteria spore CFU/m}^3 \text{ with no A/C on at } t = x} \right) \times 100 \end{aligned}$$

x = - 3, 15 and 35 min

The formula was calculated by comparing test to control runs at each time point.

#### 4. Results and Discussion:

The number of colony forming units per cubic meter of air (CFU/m<sup>3</sup>) obtained from test and control runs at each air sampling time-point were averaged and the results are reported in Tables 5.1 and 5.2 below.

**Table 5.1: Average number of CFU/m<sup>3</sup> recovered from the 3 Control Runs**


	Control 1	Control 2	Control 3	Average
-3 - 0 min	14242	15133	13584	14320
15 - 20 min	7050	9428	7967	8148
35 - 40 min	5529	6910	6533	6324

**Table 5.2: Average number of CFU/m<sup>3</sup> recovered from the 3 Test runs**

	Test 1	Test 2	Test 3	Average
-3 - 0 min	14492	16279	14595	15122
15 - 20 min	45	55	3	34
35 - 40 min	0	3	0	1

Figure 5.1 shows the the logarithmic representation of the number of *C. difficile* spores recovered at each time-point for the 3 control and 3 test runs. The concentration of *C. difficile* recovered in the control runs indicates that there was minimal natural decay. In contrast, in the

test runs there was a marked decay of *C. difficile* spores observed within 20 mins of turning the air purifier on, increasing to almost zero by the end of the test.



**Figure 5.1:** Log<sub>10</sub> concentration of *C. difficile* recovered in the test chamber in the 3 control runs with the air purifier off and in the 3 test runs with the air purifier on.

Calculation of the % reduction shows that 99.6 % of *C. difficile* spores were removed by the air purifier within the first 20 min compared to natural decay. This increased to > 99.9% after 40 min of air purifier operation.

#### 4 Conclusion

The results achieved during the testing show that the Novaerus (NV1050) demonstrated to be effective in reducing the airborne *C. difficile* by 99.6% within the first 20 min and this increased to > 99.9% after 40 min of the air purifier operation.



"This report is provided on a confidential basis for the benefit of airmid healthgroup's client pursuant to the agreement between airmid healthgroup and its client. A right of action arising under this report cannot be assigned. airmid healthgroup's responsibility under this report is limited to proven negligence and will in no case be more than the testing fees. The results shown on this test report refer only to the sample(s) tested unless otherwise stated, under the conditions agreed upon. Anyone relying on this report should understand all of the details of the engagement. Only the client is authorised to publish, copy or make this report available to any third party, and then only in its entirety. This report or the airmid healthgroup limited name or logo cannot be included in any materials, including any legal, publicity or advertising activities relating to the tested product or service without the explicit written consent of airmid healthgroup Ltd."

**Report written by:**

Naga Bonagiri MSc  
Scientific Officer

**Report reviewed by:**

**Angela  
Southey**

Angela Southey PhD, MPH  
Laboratory Manager

Digitally signed by Angela Southey  
DN: cn=Angela Southey gn=Angela  
Southey c=Ireland l=IE o=Airmid Health  
Group Ltd. ou=Airmid Health Group Ltd.  
e=asouthey@airmidhealthgroup.com  
Reason: I have reviewed this document  
Location: Dublin, Ireland  
Date: 2019-02-08 16:52Z

\*\*\*End of Report\*\*\*